#161709

V5-tagged form of JMJD6 U2OS cell line

Cat. #161709

V5-tagged form of JMJD6 U2OS cell line

Cat. #: 161709

Sub-type: Continuous

Organism: Human

Tissue: Bone

Disease: Myasthenic Syndrome

Model: Knock-Out; Knock-In

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Yvan Canitrot

Institute: Toulouse Tech Transfer

Primary Citation: Fages et al. 2020. PLoS Genet 16(6):e e1008511. PMID: 32598339.

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: V5-tagged form of JMJD6 U2OS cell line
  • Alternate name: V5-tagged form of JMJD6 deficient U2Os cell line
  • Tool sub type: Continuous
  • Parental cell: U2OS
  • Organism: Human
  • Gender: Female
  • Tissue: Bone
  • Disease: Myasthenic Syndrome
  • Morphology: Epithelial
  • Growth properties: Adherent
  • Model: Knock-Out; Knock-In
  • Model description: JMJD6 knock out using CRISPR-Cas9 and knock in of a V5-tagged form of JMJD6
  • Crispr: Yes
  • Conditional: No
  • Receptors of note: Insulin like growth factor
  • Description: V5-tagged form of JMJD6 deficient U2OS cell line used to study the role of the JMJD6 enzyme in DNA maintenance following DNA damage
  • Application: Western blot, Immunofluorescence
  • Production details: Gene inactivation by CRISPR-Cas9 and reintroduction of JMJD6 via stable expression of a plasmid coding for JMJD6
  • Biosafety level: 1
  • Recommended controls: Parental U2OS cell line, JMJD6 WT cell lines, JMJD6 deficient U2OS cell line

Target Details

  • Target: V5-tagged JMJD6
  • Target background: JMJD6 is an enzyme with intrinsic tyrosin kinase activity involved in the hydroxylation and de-methylation of histone and non-histone peptides with implications in the epigenetic changes of cancer. The jmjd6 gene also regulates its own splicing with the production of alternative splicied isoforms with different nuclear targets.

Applications

  • Application: Western blot, Immunofluorescence

Handling

  • Growth medium: DMEM medium supplemented with 10% foetal calf serum, sodium pyruvate and antibiotics (penicillin/streptomycin)
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Cultured in antibiotics: Penicillin, Streptomycin

Related Tools

  • Related tools: JMJD6 deficient U2OS cell line, Catalytically-inactive-JMJD6 U2OS cell line

References

  • Fages et al. 2020. PLoS Genet 16(6):e e1008511. PMID: 32598339.